{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:37:07Z","timestamp":1793900227416,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106066","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:22:03Z","timestamp":1770902523000},"page":"106066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant immune checkpoint inhibitors for localized dMMR\/MSI-H gastric cancer: a meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5955-8170","authenticated-orcid":false,"given":"W.K.","family":"Schwengber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3968-6618","authenticated-orcid":false,"given":"R.A.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8347-1212","authenticated-orcid":false,"given":"L.F.","family":"Leite da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6999-6019","authenticated-orcid":false,"given":"M.","family":"Tumelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-525X","authenticated-orcid":false,"given":"G.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1374","authenticated-orcid":false,"given":"P.L.S. Uson","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-1699","authenticated-orcid":false,"given":"T.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"C.","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.106066_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106066_bib2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"10184","key":"10.1016\/j.esmoop.2026.106066_bib3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"7517","key":"10.1016\/j.esmoop.2026.106066_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106066_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2026.106066_bib6","article-title":"Microsatellite instability is insufficiently used as a biomarker for Lynch syndrome testing in clinical practice","volume":"8","author":"Papadopoulou","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2026.106066_bib7","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106066_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241231259","article-title":"Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis","volume":"16","author":"Petrelli","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"10294","key":"10.1016\/j.esmoop.2026.106066_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106066_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106066_bib11","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106066_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6349","key":"10.1016\/j.esmoop.2026.106066_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.esmoop.2026.106066_bib14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106066_bib15","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106066_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106066_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106066_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106066_bib19","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106066_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102890","article-title":"How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force","volume":"134","author":"de la Fouchardi\u00e8re","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.106066_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102752","article-title":"Non-operative management after immune checkpoint inhibitors for early-stage, dMMR\/MSI-H gastrointestinal cancers","volume":"128","author":"Fazio","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.106066_bib22","article-title":"Immune checkpoint inhibitors for mismatch repair-deficient gastroesophageal adenocarcinoma: outcomes and feasibility of nonoperative management at Mayo Clinic","volume":"9","author":"Sahwan","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.106066_bib24","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.esmoop.2026.106066_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106066_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106066_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106066_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106066_bib29","article-title":"Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: the role of M2 macrophage landscape in predicting response","volume":"6","author":"Alcindor","year":"2025","journal-title":"Cell Rep Med"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106066_bib30","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2024.08.1514","article-title":"IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts","volume":"35","author":"de la Fouchardiere","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106066_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010635","article-title":"Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer","volume":"13","author":"Kang","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106066_bib32","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-25-0369","article-title":"A phase II study of perioperative avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer \u2013 the MONEO study","volume":"31","author":"Alsina","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106066_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2024.42.3_suppl.349","article-title":"Neoadjuvant toripalimab plus CapeOX in patients with localized dMMR\/MSI-H gastric or esophagogastric junction adenocarcinoma (GC\/EGJC): Results from the cohort C of phase II NICE trial","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106066_bib34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10120-022-01286-w","article-title":"A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer","volume":"25","author":"Hasegawa","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmoop.2026.106066_bib35","series-title":"Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)\/microsatellite instability (MSI) gastric carcinoma (GC): a multicenter retrospective study. Paper presented at the ESMO Congress 2024","author":"Sun","year":"2024"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106066_bib36","article-title":"Neoadjuvant immunotherapy effectiveness in patients with microsatellite instability-high (MSI-H) gastric cancer","volume":"16","author":"Chubenko","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106066_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2135819","article-title":"Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer","volume":"11","author":"Tang","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106066_bib38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12957-024-03601-4","article-title":"Neoadjuvant PD-(L)1 blockade with or without chemotherapy versus chemotherapy alone in mismatch repair-deficient, potentially resectable stage III-IV(A) gastric cancer patients: a single-center retrospective study","volume":"22","author":"Zhang","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106066_bib39","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1245\/s10434-024-16030-0","article-title":"Clinical and pathologic response to neoadjuvant immunotherapy in DNA mismatch repair protein-deficient gastroesophageal cancers","volume":"31","author":"Shannon","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106066_bib40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s10120-023-01431-z","article-title":"SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis","volume":"26","author":"Huang","year":"2023","journal-title":"Gastric Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106066_bib41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","article-title":"Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR\/MSI-H colorectal and gastric cancers","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106066_bib42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/cbt.12.8.17169","article-title":"DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells","volume":"12","author":"Iwaizumi","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106066_bib43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2026.106066_bib44","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO-25-00447","article-title":"Neoadjuvant CTLA-4\/PD-(L)1 blockade versus surgery +\/\u2212 chemotherapy in deficient mismatch repair\/microsatellite instability-high resectable gastroesophageal adenocarcinoma: individual patient data pooled analysis","volume":"43","author":"Raimondi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106066_bib45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMc2409154","article-title":"The duration of immunotherapy for mismatch repair-deficient cancers","volume":"392","author":"Rousseau","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106066_bib54","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106066_bib46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/DCR.0000000000001762","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer","volume":"63","author":"You","year":"2020","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106066_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50903","article-title":"Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial","volume":"7","author":"Thompson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2026.106066_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106066_bib49","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/annonc\/mds617","article-title":"Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort","volume":"24","author":"Cheedella","year":"2013","journal-title":"Ann Oncol"},{"issue":"10139","key":"10.1016\/j.esmoop.2026.106066_bib50","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106066_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.surg.2021.02.010","article-title":"Ninety-day mortality after total gastrectomy for gastric cancer","volume":"170","author":"Shannon","year":"2021","journal-title":"Surgery"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106066_bib52","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2026.106066_bib53","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO-25-01197","article-title":"Treat the tumor, spare the esophagus: the case for organ preservation in locally advanced esophageal\/gastroesophageal junction cancer","volume":"43","author":"Grewal","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:16:18Z","timestamp":1774487778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000086"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106066","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immune checkpoint inhibitors for localized dMMR\/MSI-H gastric cancer: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106066"}}